APA (7th ed.) Citation

Iwuji, C., Waters, L., Milinkovic, A., Orkin, C., Fox, J., Post, F., . . . Geretti, A. M. (2025). Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study). Virology Journal, 22(1), 1. https://doi.org/10.1186/s12985-025-02648-3

Chicago Style (17th ed.) Citation

Iwuji, Collins, et al. "Outcomes of Switching from Protease Inhibitor-based Antiretroviral Therapy to Bictegravir/emtricitabine/tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Adults with Nucleos(t)ide Analogue Resistance– a Phase IV Randomised, Open-label Study (PIBIK Study)." Virology Journal 22, no. 1 (2025): 1. https://doi.org/10.1186/s12985-025-02648-3.

MLA (9th ed.) Citation

Iwuji, Collins, et al. "Outcomes of Switching from Protease Inhibitor-based Antiretroviral Therapy to Bictegravir/emtricitabine/tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Adults with Nucleos(t)ide Analogue Resistance– a Phase IV Randomised, Open-label Study (PIBIK Study)." Virology Journal, vol. 22, no. 1, 2025, p. 1, https://doi.org/10.1186/s12985-025-02648-3.